Condition: Cancer · Immunotherapy · PD-1 · Sponsor: Oxford Biodynamics Inc.
The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.
This description comes directly from the study's public registry record.
Ryan Mathis, MD · 888-200-3361 · ryan.mathis@myobdx.com
Joseph DeSimone, BA · 803-329-7772 · joseph@ccorn.net
Always discuss trial participation with your own doctor first.
| Eastern Connecticut Hematology and Oncology | Norwich, Connecticut, United States | Recruiting |
| Cancer Center of Middle Georgia | Dublin, Georgia, United States | Recruiting |
| Carolina Blood and Cancer Care Associates | Rock Hill, South Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06635954